The public-private partnership Manchester Science Parks has completed a deal to buy AstraZeneca’s Alderley Park site.
The pharmaceutical company announced last March that no more R&D would take place at the Cheshire site after 2016, as it was planning to invest £330 million to establish a global R&D centre and corporate headquarters in Cambridge.
Manchester property developer Bruntwood—which is also a shareholder in Manchester Science Parks—funded the majority of the acquisition of the Alderley Park site.
This article on Research Professional News is only available to Research Professional or Pivot-RP users.
Research Professional users can log in and view the article via this link
Pivot-RP users can log in and view the article via this link.